株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

米国のてんかん市場

Epilepsy Market in the US 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 322803
出版日 ページ情報 英文 64 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
米国のてんかん市場 Epilepsy Market in the US 2015-2019
出版日: 2015年01月07日 ページ情報: 英文 64 Pages
概要

米国のてんかん市場は、2014年から2019年の間、4.85%のCAGRで拡大することが予測されています。

当レポートでは、米国のてんかん市場の現状と今後の見通しについて調査しており、市場成長因子と課題の分析、主要ベンダーのプロファイルなどを提供しています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品
    • 製品プロファイル

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 疾患の概要

  • てんかん
    • 病因
    • 兆候と症状
    • 診断
    • 疫学

第6章 イントロダクション

第7章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第8章 薬剤世代別の市場区分

第9章 購入基準

第10章 市場成長因子

第11章 成長因子とその影響

第12章 市場の課題

第13章 成長因子と課題の影響

第14章 市場動向

第15章 動向とその影響

第16章 ベンダー情勢

  • 競合シナリオ
    • 主なニュース
    • M&A
  • 市場シェア分析
    • GlaxoSmithKline
    • UCB
    • Pfizer
  • その他の有力ベンダー

第17章 主要ベンダーの分析

  • GlaxoSmithKline
  • Pfizer
  • UCB

第18章 関連レポート

目次
Product Code: IRTNTR5028

About Epilepsy

Epilepsy is a spectrum of brain disorders varying from benign to severe, disabling, and life-threatening symptoms. It is caused by various factors ranging from brain malformations and tumors to meningitis, high-risk pregnancies, and birth trauma. However, when the underlying cause of the disease is unidentified, as in the majority of the cases, it is known as idiopathic epilepsy. Epilepsy is characterized by repeated occurrence of generalized or focal seizures. An imbalance between the inhibitory and excitatory signals of the brain, leading to a sudden onset of excitation, results in seizures. Occurrence of two or more unprovoked seizures is an important criterion to diagnose a person as being epileptic.

TechNavio's analysts forecast the Epilepsy market in the US to grow at a CAGR of 4.85 percent over the period 2014-2019.

Covered in this Report

The Epilepsy market in the US can be divided into three segments: First-generation Drugs, Second-generation Drugs, and Third-generation Drugs. This report covers the present scenario and the growth prospects of the Epilepsy market in the US for the period 2015-2019. To calculate the market size, the report considers the revenue generated through the sales of anti-epileptic drugs approved in the US to treat the symptoms of epilepsy.

TechNavio's report, Epilepsy Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the Epilepsy Market in the US and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors

  • GlaxoSmithKline
  • Pfizer
  • UCB

Market Driver

  • Unmet Medical Needs
  • For a full, detailed list, view our report

Market Challenge

  • Generic Erosion
  • For a full, detailed list, view our report

Market Trend

  • Reformulation of Marketed Drugs
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
    • 03.2.1. Product Profiles

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Disease Overview

  • 05.1. Epilepsy
    • 05.1.1. Etiology
    • 05.1.2. Signs and Symptoms
    • 05.1.3. Diagnosis
    • 05.1.4. Epidemiology

06. Introduction

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Market Segmentation by Generation of Drugs

09. Buying Criteria

10. Market Growth Drivers

11. Drivers and their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Trends and their Impact

16. Vendor Landscape

  • 16.1. Competitive Scenario
    • 16.1.1. Key News
    • 16.1.2. Mergers and Acquisitions
  • 16.2. Market Share Analysis 2014
    • 16.2.1. GlaxoSmithKline
    • 16.2.2. UCB
    • 16.2.3. Pfizer
  • 16.3. Other Prominent Vendors

17. Key Vendor Analysis

  • 17.1. GlaxoSmithKline
    • 17.1.1. Key Facts
    • 17.1.2. Business Overview
    • 17.1.3. Business Segmentation
    • 17.1.4. Business Segmentation by Revenue 2012 and 2013
    • 17.1.5. Sales by Geography
    • 17.1.6. Pipeline Products
    • 17.1.7. Business Strategy
    • 17.1.8. Key Information
    • 17.1.9. SWOT Analysis
  • 17.2. Pfizer
    • 17.2.1. Key Facts
    • 17.2.2. Business Overview
    • 17.2.3. Business Segmentation by Revenue 2013
    • 17.2.4. Business Segmentation by Revenue 2012 and 2013
    • 17.2.5. Geographical Segmentation by Revenue
    • 17.2.6. Business Strategy
    • 17.2.7. Key Developments
    • 17.2.8. SWOT Analysis
  • 17.3. UCB
    • 17.3.1. Key Facts
    • 17.3.2. Business Overview
    • 17.3.3. Product Segmentation by Revenue 2013
    • 17.3.4. Product Segmentation by Revenue 2012 and 2013
    • 17.3.5. Geographical Segmentation by Revenue 2013
    • 17.3.6. Business Strategy
    • 17.3.7. Recent Developments
    • 17.3.8. SWOT Analysis

18. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Epilepsy Market in the US 2014-2019 (US$ million)
  • Exhibit 3: Epilepsy Market in the US Segmentation by Generation of Drugs
  • Exhibit 4: Prevalence of Active Epilepsy per 1,000 by age in US
  • Exhibit 5: Lamictal Revenue 2011-2013 in the US (US$ million)
  • Exhibit 6: Lamictal Sales Segmentation by Geography 2013
  • Exhibit 7: Vimpat Revenue 2011-2013 in the US (US$ million)
  • Exhibit 8: Vimpat Sales Segmentation by Geography 2013
  • Exhibit 9: Keppra Sales Segmentation by Geography 2013
  • Exhibit 10: Keppra Revenue 2010-2013 in the US (US$ million)
  • Exhibit 11: Lyrica Revenue 2011-2013 in the US (US$ million)
  • Exhibit 12: GlaxoSmithKline: Business Segmentation 2013
  • Exhibit 13: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 14: GlaxoSmithKline: Sales by Geography 2013
  • Exhibit 15: GlaxoSmithKline: Pipeline Products 2013
  • Exhibit 16: Pfizer: Business Segmentation by Revenue 2013
  • Exhibit 17: Pfizer: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 18: Pfizer: Geographical Segmentation by Revenue 2013
  • Exhibit 19: UCB: Product Segmentation by Revenue 2013
  • Exhibit 20: UCB: Product Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 21: UCB: Geographical Segmentation by Revenue 2013
Back to Top